>> THANK YOU, JOHN AND GOOD
AFTERNOON AND THANK EVERYBODY
FOR THEIR ACTUAL FORTITUDE FOR
BEING HERE ON THE AFTERNOON OF
THE SECOND DAY.
IT'S MY PLEASURE TO INTRODUCE
THE INFLUENZA WORKING GROUP
ACTIVITIES OVER THE LAST SEVERAL
MONTHS.
AND BEFORE I DO, I'D LIKE TO
ACKNOWLEDGE THE MEMBERS OF THE
WORKING GROUP WHICH IS, AS YOU
ALL KNOW, QUITE LARGE AND QUITE
A BUSY GROUP OF PEOPLE.
WE REALLY HAVE LARGE, HIGH-LEVEL
PARTICIPATION LOYAL AND
DEDICATED MEMBERSHIP.
THE GREEN ARE THE ACIP
REPRESENTATIVES ON THE WORK
GROUP AND MOST OF YOU WILL BE
FAMILIAR WITH MANY OTHERS ON THE
MEMBERS OF THE WORK GROUP.
LISTED ON THIS SLIDE ARE THE CDC
PARTICIPANTS AS WELL AS MEMBERS
FROM FDA AND HEALTH AND HUMAN
SERVICES.
AND ONCE AGAIN, THANK YOU ALL
FOR YOUR HARD WORK.
SO OVER THE LAST FEW MONTHS, WE
HAVE BEEN BUSY FINALIZING THE
PUBLICATION OF THE 2012/'13
INFLUENZA VACCINE STATEMENT.
AND WE'VE BEEN BRIEFED AND
DISCUSSED A NUMBER OF ISSUES.
THE NUMBER ONE ISSUE WE HAVE
FOCUSED ON HAS BEEN THE GRADE OF
INFLUENZA VACCINES BOTH
TRIVALENT IN CHILDREN, AND AS
YOU MAY HEAR LATER, THIS HAS
INVOLVED AN INITIAL ANALYSIS OF
STANDALONE HE KAEFFICACY,
STANDALONE
EFFICACY AND SAFETY OF LIFE
ATTENUATED AND FINALLY RELATIVE
EFFICACY OF LIVE ATTENUATED AND
INACTIVATED VACCINE.
IN ADDITION TO THIS, WE HAVE
BEEN BRIEFED BY A NUMBER OF
MANUFACTURERS ON THEIR QUAD
QUADRIVALENT AND LIVE ATTENUATED
VACCINES WHICH LIKELY WILL BE
AVAILABLE FOR THE UPCOMING
2013/2014 INFLUENZA SEASON AS
WELL AS CELL-BASED INFLUENZA
VACCINE.
IN ADDITION, WE'VE BEEN GIVEN
INFORMATION ABOUT SURVEILLANCE
FOR INFLUENZA TED AND HAVE
REVIEWED THE INFLUENZA VACCINE
COVERAGE FOR THE PAST SEASON.
SO WITHOUT FURTHER ADO, I'D LIKE
TO TURN IT OVER TO THE FIRST
SPEAKER.